Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/24/2022 | $13.00 → $6.00 | Buy | B. Riley Securities |
SCHEDULE 13G/A - MUSTANG BIO, INC. (0001680048) (Subject)
10-Q - MUSTANG BIO, INC. (0001680048) (Filer)
8-K - MUSTANG BIO, INC. (0001680048) (Filer)
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively Preclinical data support a novel combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) to optimize clinical results FDA previously granted Orphan Drug Designation to Mustang for MB-108 for the treatment of malignant glioma WORCESTER, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical b
WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1). On February 26, 2025, Mustang received formal notice from Nasdaq confirming that the Company has satisfied the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). As previously disclosed, the Company regained compliance with the minimum bid price requirement under Nasdaq Listing Rule
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang" or the "Company") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to AbbVie Bioresearch Center Inc., a Delaware corporation ("AbbVie"), for $1.0 million. Mustang has relocated its corporate headquarters to 95 Sawyer Road, Waltham, Massachusetts. Mustang expects to continue to rely on its academic part
4 - MUSTANG BIO, INC. (0001680048) (Issuer)
4 - MUSTANG BIO, INC. (0001680048) (Issuer)
3 - MUSTANG BIO, INC. (0001680048) (Issuer)
B. Riley Securities reiterated coverage of Mustang Bio with a rating of Buy and set a new price target of $6.00 from $13.00 previously
BTIG Research initiated coverage of Mustang Bio with a rating of Buy and set a new price target of $11.00
Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023 Positive topline results from two Phase 3 clinical trials evaluating DFD-29 demonstrated achievement of co-primary and all secondary endpoints versus placebo and Oracea® (doxycycline) with no significant safety issues Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in the second half of 2023 for DFD-29 and CUTX-101 Cosibelimab longer-term results demonstrated substantial increases in complete response rates in advanced cutaneous squamous cell carcinoma PDUFA goal date of January 3, 2024, set by FDA for cosi
95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd American Society of Hematology (ASH) Annual Meeting Key opinion leader conference call on Thursday, December 16, 2021, at 2:30 p.m. EST WORCESTER, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced updated data from the ongoing Phase 1/2 clinical trial of MB-106,
SC 13G/A - MUSTANG BIO, INC. (0001680048) (Subject)
SC 13D/A - MUSTANG BIO, INC. (0001680048) (Subject)
SC 13G - MUSTANG BIO, INC. (0001680048) (Subject)